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PCDII
VALIDITY AND RELIABILITY OF AN AMERICAN
TRANSLATION OF THE ST. GEORGE'S
RESPIRATORY QUESTIONNAIRE
Barr JT, Schumacher GE, Freeman S, Collette K,
PROAS Group
PROAS Group, Northeastern University and Massachusetts
Association of Cardiovascular and Pulmonary Rehabilitation,
Boston, MA, USA
A self-administered, disease-specific form of health status
instrument for patients with COPD is not available in
America. The St. George's Respiratory Questionnaire
(SGRQ) is a successful measure in Great Britain and Eu-
rope that meets these requirements, but syntax and collo-
quial differences make an American version necessary.
OBJECTIVE: To test the validity and reliability of an
American translation (ATSGRQ) of the SGRQ.
METHODS: Two bilingual health professionals indepen-
dently translated the SGRQ based on summarized input
from panels of American COPD patients and American
respiratory professionals. Consensus was reached on the
translated version and then back-translated by two other
bilingual health professionals. To establish reliability, the
ATSGRQ was given to COPD patients at the beginning
of a pulmonary rehabilitation program (PRP) and re-
peated 1 week later. To establish validity, the ATSGRQ
was used with pulmonary function tests, the Medical Re-
search Council's dyspnea scale (DYS), 6-minute walk
(6MW), and Short Form Health Status Profile-36 (SF-36)
at the beginning and end of PRP for 24 COPD patients.
RESULTS: The patients were mean age 70 yr, 40% male,
mean FEV1 = 0.95. The ATSGRQ Cronbach's alpha for
overall scale and symptom, activity, and impact compo-
nents was respectively .87, .65, .79, .80. Test-retest cor-
relations were .70, .60, .72, .64, respectively. Baseline
correlations between total ATSGRQ and FEV1, DYS,
6MW, and SF-36 physical and mental health component
scores were -.43, .54, .56, -.76, -.62. From initial to
post-PRP, the symptom ATSGRQ decreased 12.6% (p =
.004); DYS decreased 10.6% (p = .043).
CONCLUSION: Based on these preliminary data, the
ATSGRQ appears to be a valid, reliable health status in-
strument for use in an American COPD population.
PCDI2
COST OF PRESCRIPTION DRUGS AND COST OF
TREATMENT FAILURE FOR SINUSITIS
Nadesan B, Cady PS, Force RW, Force WS, Culbertson VL
Department of Pharmacy Practice and Administrative Sciences,
Idaho State University, Pocatello, ID, USA
This study shows the cost of drug treatment failure, illus-
trating the need for initial treatment success with proper
drug choice and compliance.
OBJECTIVE: This study examines the cost of prescrip-
tion drugs used in the treatment of sinusitis and the cost
of treatment failure. Economic costs are strong incentives
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to treat a disease effectively, reducing relapses and antibi-
otic resistance.
METHODS: The Idaho Medicaid database was used to
analyze drug costs. The data was divided into 2 groups, a
less than 15 but more than 1 year old group labeled
Group 1. Group 2 consisted of patients 15 or more than
15 years old. The treatment was considered a failure
when a patient returned within 30 days of a physician
visit. Thus all treatment failures could be captured.
RESULTS: There were 15,568 patients (9.8%) who had
at least one diagnosis of sinusitis, comprising 36.2%
males and 63.8% females. The total cost of prescription
drugs was $529,065. For Group 1, the total cost of drugs
for the first episode was $182,499 written for 6,594 pa-
tients. Of these, 450 patients had a treatment failure,
costing $17,365, of which Amoxicillin TriPot. Clav. ac-
counted for 31 % of drug cost. For Group 2, the total cost
of drugs for the first episode was $264,030 written for
7,107 patients. Of these, 592 patients had a treatment
failure, costing $37,183. Amoxicillin Tr/Pot. Clav. ac-
counted for 22.3% of drug cost for treatment failure.
CONCLUSION: The results show that more expensive
drugs are used for treatment failure. This is an incentive
for ensuring that a treatment succeeds with proper selec-
tion and compliance of drug therapy.
PCDI iI
DOES THE DURATION OF PULMONARY
REHABILITATION AFFECT THE
MAGNITUDE OF PATIENT RESPONSE?
Barr JT, Schumacher GE, Coleman AM, PROAS Group
PROAS Group, Northeastern University and Massachusetts
Association of Cardiovascular and Pulmonary Rehabilitation,
Boston, MA, USA
OBJECTIVE: To determine if there is a dosage effect asso-
ciated with the length of pulmonary rehabilitation (PR).
METHODS: We used a battery of outcome measures to
quantify the amount of change that was achieved from
baseline to discharge in 286 patients completing a PR
program in 1 of 12 institutions participating in PROAS.
The programs were of varying durations. Paired t-tests
indicated overall that while the pulmonary rehabilitation
programs did not yield improvements in physiologic
(FEV1, FVC, % predicted FEV1) outcomes, the patients
did achieve significant improvements in symptomatic
(Borg score), functional (6-minute walk), general health-
related quality of life [SF-36 Health Survey (SF-36)], and
disease-specific HRQL [Chronic Respiratory Disease
Questionnaire (CRQ)] variables.
RESULTS: Based on a series of stepwise multiple regres-
sions using the amount of change in each outcome variable
as the dependent variable and adjusting for the corre-
sponding baseline value and 11 clinical and sociodemo-
graphic characteristics, the number of hours of education
(HREDU, 13.5 hr ± 6.7), activities of daily living
(HRADL, 2.2 hr ± 6.6), and psychosocial support (6.5 hr ±
5.6) both individually and collectively (42.4 hr ± 11.8)
